NEA Secondary — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)
BoardJill Carroll(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Board seatAli Behbahani· per SEC Form D · $100M raise · filed Feb 2023
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSamsara BioCapitalSixty Degree CapitalSolasta Ventures+2 more
San Francisco, US
Rajaie Batniji(Executive Officer, Director)Sanjay Basu(Executive Officer, Director)
BoardVineeta Agarwala(Director)in
Board seatMohamad Makhzoumi· per SEC Form D · $22M raise · filed Nov 2023
Co-investorsAndreessen Horowitz
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.